Antitumour and antiangiogenic effects of Aplidin® in the 5TMM syngeneic models of multiple myeloma

Aplidin® is an antitumour drug, currently undergoing phase II evaluation in different haematological and solid tumours. In this study, we analysed the antimyeloma effects of Aplidin in the syngeneic 5T33MM model, which is representable for the human disease. In vitro, Aplidin inhibited 5T33MMvv DNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Caers, J, Menu, E, De Raeve, H, Lepage, D, Van Valckenborgh, E, Van Camp, B, Alvarez, E, Vanderkerken, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441967/
https://www.ncbi.nlm.nih.gov/pubmed/18521088
http://dx.doi.org/10.1038/sj.bjc.6604388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2441967/
https://www.ncbi.nlm.nih.gov/pubmed/18521088
http://dx.doi.org/10.1038/sj.bjc.6604388

Ejemplares similares